Home › Crohn's Disease › Arizona
Crohn's Disease clinical trials in Arizona
17 studies for Crohn's Disease are looking for participants at sites in Arizona.
Cities in Arizona
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- GI Alliance - Sun City ( Site 5118), Sun City
- University of Arizona Clinical and Translational Sciences Research Center ( Site 5111), Tucson
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 2, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Elite Clinical Studies /ID# 280477, Phoenix
- Gi Alliance - Arizona Digestive Health - Sun City /ID# 284084, Sun City
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- AZ Gastro Care, Chandler
- Spectrum Research Institute LLC, Gilbert
- GI Alliance- Sun City, Sun City
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 30, 2026 · NCT06581328A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- AZ Gastro Care, Chandler
- Research Solutions of Arizona, Litchfield Park
- Mayo Clinic, Scottsdale
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07196722An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Onyx Clinical Research - Site Number:8400021, Peoria
- One of a Kind Clinical Research Center AZ, LLC-Site Number: 8400061, Scottsdale
- Scottsdale Clinical Trials-Site Number: 8400145, Scottsdale
- and 1 more
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Phoenix Children's Hospital /ID# 255766, Phoenix
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 23, 2026 · NCT05995353A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- GI Alliance Sun City, Sun City
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT06045754Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Mayo Clinic Arizona, Scottsdale
Recruiting
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05230173A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Phoenix Children's Hospital, Phoenix
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Aug 3, 2026 · NCT06100289A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Phoenix Childrens Hospital, Phoenix
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 22, 2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Phoenix Children's Hospital, Phoenix
RecruitingPhase 4
Ages 6 to 17 · All sexes · Updated May 27, 2026 · NCT05781152A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Phoenix Childrens Hospital - Thomas Rd - PIN, Phoenix
RecruitingPhase 3
Ages 2 and older · All sexes · Updated May 7, 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Phoenix Childrens Hospital, Phoenix
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated May 5, 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Scottsdale Gastroenterology Specialists, Scottsdale
- GI Alliance -Gurnee, Sun City
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Apr 27, 2026 · NCT06456593A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400024, Tucson
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Mar 27, 2026 · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Scottsdale
- Mirador Therapeutics Selected Site, Sun City
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Mayo Clinic Arizona, Scottsdale
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Dec 10, 2025 · NCT06721962From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.